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Using Regression Models to Analyze
Randomized Trials: Asymptotically Valid
Hypothesis Tests Despite Incorrectly Specified
Models
Michael Rosenblum and Mark J. van der Laan
Abstract
Regression models are often used to test for cause-effect relationships from data
collected in randomized trials or experiments. This practice has deservedly come
under heavy scrutiny, since commonly used models such as linear and logistic
regression will often not capture the actual relationships between variables, and
incorrectly specified models potentially lead to incorrect conclusions. In this pa-
per, we focus on hypothesis test of whether the treatment given in a randomized
trial has any effect on the mean of the primary outcome, within strata of baseline
variables such as age, sex, and health status. Our primary concern is ensuring that
such hypothesis tests have correct Type I error for large samples. Our main result
is that for a surprisingly large class of commonly used regression models, stan-
dard regression-based hypothesis tests (but using robust variance estimators) are
guaranteed to have correct Type I error for large samples, even when the models
are incorrectly specified. To the best of our knowledge, this robustness of such
model-based hypothesis tests to incorrectly specified models was previously un-
known for Poisson regression models and for other commonly used models we
consider. Our results have practical implications for understanding the reliability
of commonly used, model-based tests for analyzing randomized trials.
1 Introduction
Data sets from randomized, clinical trials are often analyzed using models such as
linear regression, logistic regression, or Poisson regression models. The validity of
conclusions drawn from model-based analyses generally relies on the assumption
that the model is correctly specified, that is, the assumption that the statistical
model accurately represents the true data generating distribution. Robins (1994,
2004), Freedman (1997, 2008a), and Berk (2004), among others, have drawn much
needed attention to the fact that when this assumption is false it may lead to false
conclusions. Furthermore, in medical studies and studies involving biological sys-
tems in general, due to the complexity of relationships between variables, simple
regression models may fail to accurately represent the true relationships between
these variables. It may not even be possible to detect when a model is incorrectly
specified, since for the sample sizes available in many applications, diagnostics of
model fit have good power to detect only a limited number of the potential ways
that a model may fail to be correctly specified (Freedman, 2005). It is therefore
important to understand when reported results based on regression models will
be reliable, even when the models being used are incorrectly specified.
In this paper, we examine the properties of incorrectly specified regression
models (also called misspecified models) when they are used in hypothesis tests in
randomized trials. The null hypothesis we consider throughout the paper is that
the treatment being evaluated has no effect on mean outcome within subpopula-
tions defined by a given set of baseline variables. For example, in a randomized
trial of an HIV vaccine, this null hypothesis could be that the vaccine has no effect
on HIV infection rates for subpopulations defined by age, study site, and presence
of other sexually transmitted infections measured at baseline. A standard tech-
nique for testing such a hypothesis involves fitting a regression model for the mean
outcome given the treatment and baseline variables. The null hypothesis is re-
jected at level 0.05 if the 95%-confidence interval for the coefficient corresponding
to the treatment variable in this model excludes 0. When the model is correctly
specified, such a test has asymptotically correct Type I error, meaning that the
probability of rejecting the null hypothesis when it is in fact true converges to a
value at most 0.05 as sample size goes to infinity.
However, as argued by Robins (2004), for some classes of models, when the
regression model is incorrectly specified, Type I error may be quite large even for
large sample sizes. It has been an open problem to determine which models have
this problem, and which models are guaranteed to have asymptotically correct
Type I error, even when these models are misspecified.
Our main contribution is showing for a surprisingly large class of commonly
used regression models, that standard hypothesis tests based on these models (but
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using robust variance estimators) are protected from the above problem. That is,
for this large class of regression models, the corresponding hypothesis tests are
guaranteed to have asymptotically correct Type I error, regardless of whether the
actual data generating distribution behaves according to the model or not. This
is a non-trivial result, since the regression models we consider will in general be
incorrectly specified even under the null hypothesis of no mean treatment effect
within strata of baseline variables. Our results enable the use of the model-
based tests described in Section 4, without fear of inflated Type I error, at least
asymptotically, under the assumptions given in Section 3.
Examples of this robustness to misspecified models, for some types of linear
regression models, have been shown in (Robins, 2004; Freedman, 2008a). We show
that this property of robustness to incorrectly specified models holds for two very
large classes of commonly used models. First, we show it holds for a large class
of linear regression models and give a simple procedure for augmenting any linear
model to ensure it has this robustness property. Second, we show the robust-
ness property holds for many commonly used models including logistic regression
models, probit regression models, binary regression models with complementary
log-log link, and Poisson regression models; the main requirement is that the lin-
ear part in such models be of a certain commonly used form that we describe in
Section 5.
Important work has been done using semiparametric methods to construct
estimators and hypothesis tests that are robust to incorrectly specified models in
the setting of randomized trials, for example (Robins, 1986, 1994; van der Laan
and Robins, 2002; Tsiatis et al., 2008; Zhang et al., 2008; Moore and van der Laan,
2007; Rubin and van der Laan, 2007). The emphasis of this paper, in contrast,
is on standard regression-based methods. Regression-based methods have the
advantage that they may be more familiar to many statisticians, who already
have much expertise implementing regression analyses in statistical software.
Throughout the paper, we assume the true data generating distribution, which
is unknown to the experimenter, may not be in the experimenter’s model. We
only make the following three assumptions on the data generating distribution:
treatment is randomly assigned, all variables are bounded, and each subject’s data
is i.i.d. from an unknown distribution. The first assumption will be true in all
randomized trials. The second holds for most variables of interest. The latter
assumption, also made in (Robins, 2004; Tsiatis et al., 2008; Zhang et al., 2008;
Moore and van der Laan, 2007), will only be true in some types of randomized
trials; we explain this further in the discussion section. The focus of this paper
is hypothesis testing, and we note that our robustness results do not, in general,
imply analogous results for estimation; we discuss this issue in Section 8.
In the next section, we give an example that typifies how regression models
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are used to draw conclusions from randomized trials, and we show how our results
apply to this example. We describe the hypothesis testing problem and robustness
property considered in this paper in Section 3. In Sections 4 and 5 we give our
main results in terms of robustness of certain regression-based hypothesis tests
to incorrectly specified models. In Sections 6 and 7, we use simulations and a
data example from a recently completed randomized trial (Padian et al., 2007)
to compare the performance of regression-based hypothesis tests to other robust
methods. We discuss the practical implications of our results in Section 8 and
defer all proofs to the Web Appendices. (The URL for the Web Appendices is
given at the end of the paper.)
2 Example of a Regression-Based Hypothesis
Test in a Randomized Trial
To illustrate how our results are motivated by issues arising in the analysis of
clinical trials, we consider the recently completed “Randomized Trial of Inhaled
Cyclosporine in Lung-Transplant Recipients” (Iacono et al., 2006). The treatment
was an inhaled drug to help prevent rejection after lung transplantation. Half
the subjects were randomly assigned a placebo drug. The primary outcome was
the number of severe (grade 2 or higher) rejection events per year of follow-up
time. We refer to this count using the variable REJECTIONS. In one of the
main analyses, a Poisson regression model was used to test for differences in mean
outcome between the treatment group and control group, within subpopulations
defined by several baseline variables. These baseline variables included indicators
of whether there was a serologic mismatch between donor and recipient (denoted
by V1), and of whether a rejection episode had occurred before the first inhaled
treatment was given (denoted by V2). We denote the treatment group by A = 1
and the control group by A = 0. The Poisson model specifies that the logarithm of
the conditional mean of the variable REJECTIONS given treatment and baseline
variables has the form:
log E(REJECTIONS | A, V1, V2) = β0 + β1A+ β2V1 + β3V2. (1)
(Throughout the paper, log refers to the natural logarithm.) The model also
specifies that conditioned on A, V1, V2, the variable REJECTIONS has a Poisson
distribution.
This Poisson model was used to carry out a hypothesis test of whether there
was any mean treatment effect within strata of baseline variables V1, V2. First,
the model was fit using maximum likelihood estimation, giving an estimate of the
3
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coefficient vector β. Then, if the 95% confidence interval around the estimate for
the coefficient β1 were found to exclude 0, it would be concluded that there was
a statistically significant difference in the outcome due to the treatment (inhaled
cyclosporine). (In the case of this trial, the observed difference turned out not to
be statistically significant.)
Standard arguments to justify the validity (in terms of Type I error) of such
model-based hypothesis tests rely on the model being correctly specified, at least
approximately. In the above example, there is no a priori reason to think this
should be the case, and no reason based on subject-knowledge about rejection
events in lung transplant recipients is given in the paper. Thus, it may be the
case that the above model is not correctly specified. Our goal in presenting this
example is not to criticize a particular analysis. We merely wanted to illustrate the
commonly used practice of model-based hypothesis tests in randomized trials, and
point out the potential for models to be misspecified. Freedman (2008a) provides
many other examples of randomized trials in which regression models are used.
Our main result provides asymptotic guarantees for Type I error without hav-
ing to assume the model is correctly specified. In particular, our results imply
that the above hypothesis test will have asymptotically correct Type I error, if
the confidence interval is instead computed using the sandwich estimator of Huber
(1967) (described in detail in Web Appendix B), and if the subjects represent a
random sample from a larger population. In this case, with probability tending
to 0.95, for large sample sizes, one is protected against falsely concluding there is
a mean effect of the treatment within some stratum of the baseline variables V1
and V2, when no such effect exists, even when the model used is misspecified.
3 Notation, Assumptions, Hypothesis Testing
Problem, and Robustness Property
We now explain the underlying assumptions and goal of the hypothesis testing
problem that we address in the remainder of the paper. We start by introducing
our notation. Let Y represent the outcome of interest, A represent the treatment
assignment, and V represent a vector of baseline variables such as age, sex, and
past health status. We assume there are k different treatments being evaluated in
the randomized trial, so that A takes values in {0, . . . , k − 1}; many randomized
trials have k = 2, corresponding to a single treatment (A = 1) being compared to
a control (A = 0). We consider regression models m(A, V |β) of the mean outcome
given treatment and baseline variables: E(Y |A, V ). Some of these models (e.g.
Poisson regression) specify additional characteristics of the distribution of Y . As
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a technical condition, we assume all variables are bounded1. We also note that
all of our results hold even when the regression model used (such as a Poisson
regression model) assumes that variables are unbounded. This is because, as
discussed below, our results hold whether or not the assumptions underlying the
regression model are true. Our results, however, only guarantee asymptotically
correct Type I error, and we note that when the regression model used is a poor
approximation to the true data generating distribution, this may result in low
power, as discussed in Section 6.
Since we never assume that the model m(A, V |β) is correctly specified, it may
be better to think of it as a “working model”; that is, since we never assume the
data generating distribution obeys the constraints of the model, m(A, V |β) can
be considered merely as a mathematical formula given as input, along with the
data, to a hypothesis testing procedure. For example, the Poisson model (1) in the
previous section can be viewed as a working model, that is, simply a formula used
by statistical software to generate a 95%-confidence interval for the coefficient β1;
this confidence interval is used to decide whether to reject the null hypothesis or
not, depending on whether it excludes 0. The purpose of this paper is to prove
guarantees for the Type I error of such hypothesis testing procedures, without
assuming the model is correctly specified.
The only assumptions we make on the data generating distribution are that
each subject’s data is i.i.d. from an unknown distribution (which is a common
assumption in the superpopulation inference framework, further discussed in Web
Appendix F), that all variables are bounded, and that treatments are randomly
assigned. We also prove our results under a modified set of assumptions that
better represents the actual way in which data is generated in randomized trials;
in particular, these modified assumptions allow for treatment being randomly
assigned to fixed proportions of the study subjects, instead of being assigned i.i.d.
This modified set of assumptions is given in Web Appendix D.
Our focus throughout the paper is testing the null hypothesis of no mean treat-
ment effect within strata of a set of baseline variables V . More formally, we define
our null hypothesis as follows:
Null Hypothesis: For all treatments a1, a2,
E(Y |A = a1, V ) = E(Y |A = a2, V ). (2)
The above expectations are taken with respect to the true data generating distri-
bution.
1Boundedness of variables is used in our proofs to establish integrability of the log-likelihood
and its first two derivatives. We find the boundedness assumption natural in that most variables
in practice will have minimum and maximum possible values.
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Because we assume the data come from a randomized trial, E(Y |A = a, V = v)
has a causal interpretation as the mean outcome that would have been observed
had everyone with baseline variables V = v in the population from which the trial
participants were drawn been assigned treatment A = a. Cast in this light, our
null hypothesis is that the treatment has no effect on the mean outcome, within
strata of baseline variables.
Note that this null hypothesis is weaker than the null hypothesis of no effect
at all of treatment on the distribution of the outcome within such strata2; our
null hypothesis only posits that the mean of the outcome within such strata is not
affected by which treatment is administered. However, in the special case that Y
is binary, so that the conditional mean of Y characterizes the entire conditional
distribution of Y , our null hypothesis simplifies and is equivalent to no effect at
all of treatment on the distribution of the outcome within strata of V . In this
case, certain permutation tests can also be used to test our null hypothesis; we
will compare the power of our regression-based tests to a permutation test of
Rosenbaum (2002) in Section 6. Throughout this paper, we are concerned with
testing the null hypothesis (2); however, in Web Appendix C we also prove a
result for testing a different type of null hypothesis–that of no effect modification
by baseline variables.
The property we will prove for hypothesis tests based on many commonly used
regression models is the following:
Robustness Property: (3)
We say a hypothesis test at level α is asymptotically robust to misspecification if
for any data generating distribution satisfying the above null hypothesis (2), the
asymptotic probability of rejecting the null hypothesis is at most α. If a hypothesis
test satisfies this property at all levels α, we simply say it is asymptotically robust
to misspecification.
2In our framework, we say there is no effect at all of treatment on the distribution of the
outcome within strata of V if the treatment A is mutually independent of baseline variables V
and outcome Y .
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4 Main Result
Our main result is that for a large class of commonly used regression models, a
type of hypothesis test (that we describe in detail below) based on such models
has the robustness property (3). We make the following assumptions:
(A1) The data are generated as described in Section 3.
(A2) A regression model m(A, V |β) in one of the classes given in Section 5 below
is used. For example, if the outcome is dichotomous, one could use the
logistic regression model
m(A, V |β) = logit−1(β0 + β1A+ β2V + β3AV ). (4)
(A3) βi is a pre-specified coefficient of a term containing the treatment variable
A in the linear part of the model chosen in (A2). For example, if using the
logistic model (4), one could specify either β1 or β3. One can also use more
than one of these coefficients. For example, one could use both β1 and β3 if
using the logistic model (4).
Consider the following hypothesis test:
Hypothesis Test: (*)
For concreteness, we consider the case of testing at level α = 0.05. The parameter
β is estimated with ordinary least squares estimation if the model used is linear;
otherwise it is estimated with maximum likelihood estimation. The standard er-
ror is estimated by the sandwich estimator, which can easily be computed with
standard statistical software; we describe the sandwich estimator in detail in Web
Appendix B. If a single coefficient βi is chosen in (A3), then the null hypothesis of
no mean treatment effect within strata of V is rejected at level 0.05 if the estimate
for βi is more than 1.96 standard errors from 0. If several coefficients are chosen
in (A3), one can perform a similar test based on a Wald statistic that uses the
estimates of these coefficients along with their covariance matrix based on the
sandwich estimator; we describe this procedure in Web Appendix B.
We note that in some cases, such as when the design matrix is not full rank or
the maximum likelihood estimator fails to converge, the estimators we consider
will be undefined. We therefore specify that regardless of whether the estimate for
the coefficient βi is more than 1.96 standard errors from 0, we always fail to reject
the null hypothesis if the design matrix has less than full rank or if the maximum
likelihood algorithm fails to converge. Since standard statistical software (e.g.
Stata or R) will return a warning message when the design matrix is not full rank
7
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or when the maximum likelihood algorithm fails to converge, this condition is easy
to check.
The main result of this paper is the following theorem (proved in Web Ap-
pendix D):
Theorem: Under assumptions (A1)-(A3), the hypothesis test (*) has the ro-
bustness property (3). That is, it has asymptotic Type I error at most 0.05, even
when the model is misspecified.
We point out that the above theorem is non-trivial, since the regression models
in the two classes we describe in Section 5 below will generally be incorrectly
specified if V is high-dimensional, under the null hypothesis (2). This follows
since even under this null hypothesis of E(Y |A, V ) = E(Y |V ), a correct model of
E(Y |V ) would have to exactly capture how the mean of the outcome Y depends on
the baseline variables V ; when V is high-dimensional, this is generally impossible
unless the mechanisms that determine Y have simple, well understood functional
forms.
We briefly outline the main steps in the proof of the above theorem; read-
ers who are mainly interested in the application of this method in practice may
prefer to skip to Sections 5-7. The full proof of the above theorem is given in
Web Appendix D. The main work of the proof is showing that under the as-
sumptions (A1)-(A3) above, the estimate βˆi of the coefficient βi is asymptotically
normal, and converges to 0 under the null hypothesis (2). Once this is proved,
the theorem follows from the fact that robust variance estimates computed by
the sandwich estimator are asymptotically correct even for misspecified models.
That βˆi is asymptotically normal follows from a standard result characterizing
the convergence of maximum likelihood estimators for generalized linear models,
as given in Theorem 5.23 in (van der Vaart, 1998, pg. 53). It remains, then, to
show that under the null hypothesis (2), βˆi converges to 0 as sample size goes to
infinity. The proof of this fact is the main technical contribution of this paper. It
relies on A being independent of V (as is the case in a randomized trial), on the
null hypothesis (2), and on the exponential form of the likelihood for generalized
linear models.
5 Classes of Regression Models that Guarantee
the Robustness Property
We now describe two classes of regression models that can be used in the hypoth-
esis test described in the previous section; when any of these models is used, the
8
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resulting hypothesis test is guaranteed to have the robustness property (3). We
emphasize that these models are considered ”working models,” in that we never
assume they are correctly specified. We first give a class of linear models and then
give a class of generalized linear models. The choice of model can have a large
effect on the power of the hypothesis test, which we explore in Section 6 below
and in Web Appendix A. Note that the choice of which model to use must be
made prior to looking at any of the data from the randomized trial. Otherwise,
the risk of such data snooping would be that Type I error could be increased.
5.1 Linear Models
We exactly characterize the class of linear models for which the hypothesis test
(*) has the robustness property (3).
Before giving a formal characterization of this class in (5) below, we give
an informal description and several examples. Consider the special case of A a
binary treatment, taking values 0 and 1. Roughly speaking, a linear model is in
our class if for every term f(A, V ) in the model, the terms f(1, V ) and f(0, V ) are
contained in the model as well, or else these corresponding terms must be linear
combinations of other terms in the model. For example, the linear model
m1(A, V |β) = β0 + β1A+ β2V,
is in our class, since corresponding to the A term, we also have an intercept term.
Also, the following models are in our class:
m2(A, V |β) = β0 + β1A+ β2V + β3AV,
m3(A, V |β) = β0 + β1A+ β2V + β3AV + β4V
2 + β5AV
2,
since for the term AV we have the corresponding main term V , and for the term
AV 2, we have corresponding term V 2.
The following model
m4(A, V |β) = β0 + β1e
V + β2e
(2A−1)V ,
does not contain a term (or linear combination of terms) corresponding to setting
A = 0 in e(2A−1)V , is not in our class of models, and does not have the robustness
property (3). However, if we set A = 0 in e(2A−1)V , producing the term e−V , and
add this term to the above model, we get the following model that is in our class:
m5(A, V |β) = β0 + β1e
V + β2e
−V + β3e
(2A−1)V ,
9
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and so has the robustness property (3). This illustrates a general method by
which one can add terms to any existing linear model to obtain a model with the
robustness property (3).
In the above models m1, m2, m3, all terms containing the treatment variable A
are a product of a function of A and a function of the baseline variables V . The
class of linear models of this form, in which for each such product term f(A)g(V )
the model also contains the term g(V ), was shown by Robins (2004) to have the
robustness property (3). Our result extends Robins’ class to a larger class of
linear models which we formally define next. This larger class includes model m5
for example. We show in Web Appendix D that this larger class is the largest
possible, in that it contains all linear models having robustness property (3).
We now formally define our class of linear models to be all models of the form:
m(A, V |β) =
∑
j
β
(0)
j fj(A, V ) +
∑
k
β
(1)
k gk(V ), (5)
where {fj , gk} can be any functions bounded on compact sets such that for each
term fj(A, V ), we have E(fj(A, V )|V ) is a linear combination of terms {gk(V )}.
We denote the parameter vector (β(0), β(1)) simply by β. Since our setting is a
randomized trial in which the probabilities of treatment assignment A are inde-
pendent of baseline variables V and are set by the experimenters, one can always
directly compute the conditional expectations E(fj(A, V )|V ) =
∑
a fj(a, V )p(a).
The theorem in Section 4 states that when the hypothesis test (*) uses a
linear model of type (5), it has the robustness property (3), which guarantees
asymptotically correct Type I error for testing the null hypothesis (2) even when
the model is misspecified. The converse is also true. That is, when the hypothesis
test (*) uses a linear model not having the property described just after (5), but
for which the terms are linearly independent, then it will not have the robustness
property (3). This is proved in Web Appendix D.
5.2 Generalized Linear Models
In this section we define our class of generalized linear models for which the
hypothesis test (*) has the robustness property (3). Before giving a formal char-
acterization of our class of generalized linear models in (6) below, we give an
informal description and some examples. Consider the following types of gener-
alized linear models: logistic regression, probit regression, binary regression with
complementary log-log link function, and Poisson regression with log link function.
A generalized linear model is in our class if it is of one of these types, and if the
linear part is of a commonly used form defined precisely in (6) below. We now give
10
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specific examples of generalized linear models in this class. We show just a few of
the many possibilities. Note that the linear parts (for example, β0 + β1A + β2V )
shown in any of the models below can be used in any of the other models.
Examples of Generalized Linear Models for which Robustness Prop-
erty 3 Holds:
1. Logistic Regression: For Y binary and logit(x) = log(x/(1−x)), the follow-
ing model for P (Y = 1|A, V ):
m6(A, V |β) = logit
−1 (β0 + β1A+ β2V ) ,
2. Probit Regression: For Y binary and Φ(x) the cumulative distribution func-
tion of the standard normal, the following model for P (Y = 1|A, V ):
m7(A, V |β) = Φ (β0 + β1A+ β2V + β3AV ) .
3. Binary Regression with complementary log-log link function: The comple-
mentary log-log function is ζ(µ) = log(− log(1 − µ)). The following model
for P (Y = 1|A, V ):
m8(A, V |β) = ζ
−1
(
β0 + β1A+ β2V
2 + β3AV
2
)
.
4. Poisson Regression: For Y a “count” (that is, Y a nonnegative integer), the
Poisson (log-linear) model:
logm9(A, V |β) = β0 + β1A+ β2V + β3AV.
We now give a formal description of the generalized linear models in our class.
Consider the following types of generalized linear models3: logistic regression,
probit regression, binary regression with complementary log-log link function, and
Poisson regression with log link function. We define our class of generalized linear
models to be any generalized linear model from the previous list, coupled with a
linear part of the following form:
η(A, V |β) =
∑
j
β
(0)
j fj(A)gj(V ) +
∑
k
β
(1)
k hk(V ), (6)
for any measurable functions {fj , gj, hk} such that for all j, there is some k for
which gj(V ) = hk(V ); we also assume the functions {gj, hk} are bounded on
3See McCullagh and Nelder (1998) for more details on generalized linear models.
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compact subsets of Rq, where V has dimension q. Note that (6) is more restrictive
than the constraint (5) on linear models above, but includes many models used
in practice (such as the models given as examples above). A model being in this
class is a sufficient condition, but not a necessary condition, for the hypothesis
test (*) to have the robustness property (3).
Our results also hold for other families of generalized linear models, such as
Gamma and Inverse-Gaussian models with canonical link functions, but certain
regularity conditions4 are needed for the robustness property (3) to hold in these
cases. For the models described above, no regularity conditions beyond those
given just after (5) and (6) are needed.
6 Simulation Studies
We use simulations to compare the power of the regression-based method of this
paper to other hypothesis testing methods. Model-based hypothesis tests have
been shown to sometimes have more power than the intention-to-treat based hy-
pothesis test (Robinson and Jewell, 1991; Herna´ndez et al., 2004; Moore and
van der Laan, 2007). However, depending on the data generating distribution
and working model used, model-based hypothesis tests can also have lower power
than the intention-to-treat based test. In this section, we examine the power of
six robust methods under various data generating distributions. We only present
the results of one set of simulations that are representative of the findings from a
larger set of simulations; this larger set of simulations is given in Web Appendix
A.
For simplicity, we consider randomized experiments with binary outcome Y ,
two possible treatments A = 0 and A = 1, and a continuous-valued baseline vari-
able V . The hypothesis being tested is that of no mean treatment effect within
strata of this baseline variable, as formally defined in (2). Since the robustness
property (3) is the main focus of this paper, we chose to compare the method
of this paper to other methods that also have this robustness property. Below,
we give summaries of the methods we will be comparing, each of which has the
robustness property (3); detailed descriptions are given in Web Appendix A.
Hypothesis Testing Methods:
M0: Regression-based test: This is the hypothesis testing method (*) de-
scribed in Section 4. The estimated coefficients corresponding to all terms
4These regularity conditions are primarily technical, and result from the fact that for Gamma
and Inverse-Gaussian models, the log-likelihood is only defined when the linear part η(A, V |β)
in (6) above is strictly positive.
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in the working model that contain the treatment variable are combined into
a Wald statistic, as described in Web Appendix B.
M1: Intention-to-treat based test: Estimate the risk difference by taking the
difference between the empirical means of the two treatment groups. Reject
the null hypothesis whenever the 95% confidence interval for the estimated
risk difference excludes 0.
M2: Cochran-Mantel-Haenszel test: (Cochran, 1954; Mantel and Haenszel,
1959) First, the baseline variable is discretized. Then, the Cochran-Mantel-
Haenszel test is run.
M3: Permutation test: (Rosenbaum, 2002) First, the binary outcome Y is
regressed on the baseline variable V using logistic regression. Pearson resid-
uals for each observation are calculated based on the model fit. Then, the
residuals for observations in which A = 1 are compared to those for A = 0
using the Wilcoxon rank sum test.
M4: Targeted Maximum Likelihood based test: (Moore and van der Laan,
2007; van der Laan and Rubin, 2006) The risk difference is estimated, ad-
justing for the baseline variable using the targeted maximum likelihood ap-
proach; the null hypothesis is rejected if the 95% confidence interval for the
risk difference excludes 0.
M5: Augmented Estimating Function based test: (Tsiatis et al., 2008;
Zhang et al., 2008) The log odds ratio is estimated, using an estimating
function that is augmented to adjust for the baseline variable; the null hy-
pothesis is rejected if the 95% confidence interval for the log odds ratio
excludes 0.
In all the scenarios we consider below, the data consist of 200 independent,
identically distributed samples drawn from a data generating distribution P . Each
observation consists of a single baseline variable V , a binary treatment A, and a bi-
nary outcome Y . First, we generate the baseline variables V from a mixture of two
normal distributions with variance 1 and with probability 1/2 of being centered
at 0 or 1. The randomized treatment A is then generated, with probability 1/2 of
being 0 or 1, independent of V . Lastly, the outcome Y is generated according to
a logistic regression model for the probability that Y = 1 given treatment A and
baseline variable V . We consider three different such logistic regression models,
each of which leads to a different data generating distribution. The first contains
just the treatment: P (Y = 1|A, V ) = logit−1(A); the second contains the treat-
ment and the baseline variable as main terms P (Y = 1|A, V ) = logit−1(A + V );
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and the third contains both main terms and an interaction term P (Y = 1|A, V ) =
logit−1(A+V −AV ). This completes the description of the three data generating
distributions used below, which we call data generating distributions 1, 2, and 3,
respectively.
We next define the three working models used by the above methods in our
simulations. Methods M0, M4, and M5 require working models for the probability
that the outcome Y equals 1, given the treatment A and the baseline variable V .
We define Working Model 1 as
logit−1 (β0 + β1A+ β2V + β3AV ) . (7)
This is a correctly specified model for the data generating distributions above.
Working Models 2 and 3 are misspecified models. Working Model 2 has the
wrong functional form, and Working Model 3 uses a ”noisy” version of the base-
line variable V (to represent the effect of measurement error). These working
models are fully described in Web Appendix A. We point out that methods M1
and M2 do not use working models. Also, the permutation-based method M3
requires working models for the probability that the outcome Y equals 1, given
just the baseline variable V ; we define working models for method M3, analogous
to those defined above, in Web Appendix A, where we also give the R code for
our simulations.
Table 1 gives the approximate power, based on 100,000 Monte Carlo simu-
lations, of methods M0-M5, under the three data generating distributions and
three working models defined above. The columns correspond to data generating
distributions 1, 2, and 3, respectively. The rows are in blocks corresponding to
Working Models 1, 2, and 3, respectively. Starting in the leftmost column, we see
that all methods have roughly the same power (about 90%), except method M0
(regression-based method of this paper) and sometimes M3 (permutation-based)
have less power (as low as 81%). As one goes from left to right in the table,
corresponding to going from data generating distribution 1 to 2 to 3, all methods
except M0 consistently lose power. This is because both the risk difference and
odds ratio decrease as we go from data generating distribution 1 to 2 to 3, and
all methods except M0 generally have less power at alternatives for which the risk
difference and odds ratio are smaller. Method M0, in contrast, has more power
than the other methods at data generating distribution 3 (representing interac-
tion between the treatment and baseline variable). Method M0 is better able, at
least in these simulation examples and the simulations in Web Appendix A, to
take advantage of the interaction effect, since method M0 is based on estimated
regression coefficients corresponding to both the main term A and the interaction
term AV .
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Comparing the power of methods M0-M5 when using correctly specified Work-
ing Model 1 vs. misspecified Working Models 2 and 3, we see that misspecifica-
tion reduces the power of all methods (except the intention-to-treat method M1,
which completely ignores baseline variables). See Web Appendix A for more sim-
ulations, in which the power of methods M0-M5 is compared for different sample
sizes, data generating distributions, and working models. Also in Web Appendix
A, we consider the following: Type I error at various sample sizes, the impact
of using different sets of coefficients in hypothesis test (*), and the possibility of
combining several test statistics based on different methods or working models.
7 Data Example from Randomized Trial
We apply the regression-based hypothesis test (*) to the data from a recently
completed randomized trial. The Methods for Improving Reproductive Health in
Africa (MIRA) randomized trial (Padian et al., 2007) investigated the effect of
diaphragm and lubricant gel use in reducing HIV infection rates among susceptible
women. 5,045 women were randomly assigned either to the active treatment arm
(which we call the ”diaphragm arm”) or to the control arm. By the end of the trial,
there were 158 HIV infections in the diaphragm arm and 151 HIV infections in the
control arm. The intention-to-treat analysis for the risk difference yielded the 95%
confidence interval (-0.02, 0.01). This is strong evidence that the intervention has
little or no effect on overall HIV rates, but the question remained as to whether the
diaphragm intervention may have an effect for some high-risk subpopulations. The
principal investigators identified five baseline variables they thought indicative of
HIV risk: age, condom use reported at baseline, prevalence of HSV5 infection, a
composite indicator of subject risk behavior, and a composite indicator of partner
risk6. We denote these variables by V1, V2, V3, V4, V5, respectively. Traditional
subgroup analyses, which would test for an effect within subgroups defined by each
such variable, would require adjustment for multiple testing. A single hypothesis
test can have more power. We show next how to use the regression-based method
of this paper to carry out such a single test. We note that since we are testing this
hypothesis post-hoc (after having seen the data), we must interpret any results
with much caution; the goal here is to illustrate the application of the regression-
based method of this paper in a real data example. In general, one should pre-
specify such an analysis as a secondary analysis in the study protocol.
We now describe how a hypothesis test of type (*) from Section 4 can be
5herpes simplex virus 2
6The indicators of subject risk behavior and partner risk are defined in Table 3 on page 7 of
(Padian et al., 2007).
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Table 1: Power of methods M0-M5. Sample size is 200 subjects. The data gen-
erating distributions corresponding to each column and the working models used
are described in Section 6. ”C-M-H test” below is an abbreviation for ”Cochran-
Mantel-Haenszel test.” Distributions 1, 2, and 3 are defined in the text.
Power When Data Generated from:
Distribution 1 Distribution 2 Distribution 3
Hypothesis
Testing Methods
Using Working Model 1
(Correctly Specified)
M0: Regression Based 0.86 0.71 0.93
M1: Intention-to-Treat 0.93 0.76 0.52
M2: C-M-H Test 0.90 0.79 0.49
M3: Permutation Based 0.92 0.79 0.64
M4: Targeted MLE 0.92 0.83 0.54
M5: Aug. Estimating Fn. 0.92 0.83 0.53
Using Working Model 2
(Wrong Functional Form)
M0: Regression Based 0.85 0.65 0.60
M1: Intention-to-Treat 0.93 0.76 0.52
M2: C-M-H Test 0.91 0.73 0.48
M3: Permutation Based 0.81 0.67 0.48
M4: Targeted MLE 0.93 0.76 0.52
M5: Aug. Estimating Fn. 0.92 0.76 0.52
Using Working Model 3
(Containing Measurement Error)
M0: Regression Based 0.85 0.65 0.62
M1: Intention-to-Treat 0.93 0.76 0.52
M2: C-M-H Test 0.90 0.74 0.48
M3: Permutation Based 0.81 0.69 0.52
M4: Targeted MLE 0.92 0.78 0.52
M5: Aug. Estimating Fn. 0.92 0.78 0.52
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applied to test the null hypothesis of no mean treatment effect within strata of
the above baseline indicators of HIV risk. To carry out hypothesis test (*), we
first need to specify a regression model for the probability of HIV infection by the
end of the trial, given treatment arm A and baseline variables V1, V2, V3, V4, V5.
We used the logistic regression model
m(A, V |β) = logit−1(β0 + β1A+ β2V1 + β3V2 + β4V3 + β5V4 + β6V5
+β7AV1 + β8AV2 + β9AV3 + β10AV4 + β11AV5). (8)
We also need to pre-specify a set of coefficients corresponding to terms con-
taining the treatment variable, to use in the test. We used all such coefficients
(i.e. β1, β7, β8, β9, β10, β11), but in general the question of which set of coefficients
to choose in order to have the most power is an open problem and area for future
research that we discuss in Web Appendix A. This logistic model was fit using
standard software (see R code in Web Appendix E), yielding coefficient estimates
and robust standard errors as given in Table 7 in Web Appendix E. Based on these
estimated values, we constructed a Wald statistic, as described in Web Appendix
B. This resulted in p-value 0.97. We note that the p-value is quite similar when
using link functions other than the logit link; for the probit link, the p-value is
0.98, and for the complementary log-log link, the p-value is 0.97. The p-value
when using a logistic regression model containing only main terms is 0.67.
The hypothesis test just described has asymptotically correct Type I error,
even if the logistic regression model (8) is misspecified, under the assumptions
given in Sections 3 and 4. Had this test rejected the null hypothesis, this would
have been evidence that within some stratum of the variables V1, V2, V3, V4, V5
(which are thought to indicate HIV risk), the diaphragm intervention has an
effect. This information could be useful in assessing whether the diaphragm and
gel provide protection against HIV in at least some circumstances, which would
be an important result (for example, suggesting the potential role of the cervix,
which a latex diaphragm is designed to protect, in HIV transmission).
We now consider applying the alternative methods M1-M5 given in Section 6
to this data example. Given that the intention-to-treat analysis effectively rules
out there being a strong overall mean effect of the intervention, it does not make
sense to apply methods M2, M4, or M5; this follows since these methods have
low power at alternatives for which the overall risk difference is close to 0 and the
overall odds ratio is close to 1, which is the case in this data set. It does make sense
to apply method M3 (the permutation-based test of Rosenbaum (2002)), since this
method can have adequate power at alternatives where there is no overall mean
effect, as long as there is a strong effect within some stratum of baseline variables.
We applied method M3 (see Web Appendix E for R code), resulting in p-value
0.88.
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8 Discussion
Regression models are often used to analyze randomized trials. However, in med-
ical studies, due to the complexity of relationships between variables, simple re-
gression models may fail to accurately represent the true relationships between
these variables. Thus, it is important to know whether hypothesis tests based on
regression models will be robust to misspecification of these models. Our contri-
bution in this paper is showing that for many commonly used regression models,
hypothesis tests based on these models are guaranteed to have asymptotically cor-
rect Type I error, even when the model is incorrect, in certain types of randomized
trials. We showed in Section 5 how to augment linear models so that they will
have this robustness property. Our results provide a strong motivation for using
robust variance estimates whenever model-based hypothesis tests are used.
A limitation of our results is that they are asymptotic, guaranteeing correct
Type I error only in the limit as sample size goes to infinity. We examine Type I
error of the methods considered in this paper (M0-M5 from Section 6), for sample
sizes ranging from 200 to 400 subjects, in Web Appendix A; for all the methods,
and for all the data generating distributions and working models we considered,
the Type I error at nominal level α = 0.05 was always at most 0.06, and most
often was at most 0.05.
Another limitation of our robustness results is that they are only proved for
data obtained from randomized trials in which, in addition to treatment being
randomly assigned to study subjects, the data on each subject is (approximately)
i.i.d. from an unknown distribution. This is a limitation since the subjects actually
recruited in medical randomized trials are screened for entry criteria, and thus
in many cases may best be considered a convenience sample (Freedman et al.,
2007, appendix to chap. 27). We conjecture that our results will hold in such
a setting, under the weaker set of assumptions made in (Freedman, 2008b), but
this is an open problem. We note, however, that our assumption that subject
data is approximately i.i.d. may not be as restrictive as it seems. For example,
subject data may be approximately i.i.d. not from a distribution corresponding
to the general population, but from a distribution corresponding to those in a
population who meet the entry criteria of a trial and who would be willing to
participate.
An alternative set of methods that adjust for baseline variables in randomized
experiments and that use regression models as working models, are the exact per-
mutation tests of Rosenbaum (2002). These methods have been shown to have
correct Type I error, even when working models are misspecified, but under a
different framework (called randomization inference) than used in this paper. We
give a detailed comparison of the assumptions of this paper and the randomization
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inference assumptions of Rosenbaum (2002) in Web Appendix F. Because of this
difference in assumptions, it is in general difficult to devise a fair comparison of our
methods and the randomization inference methods of Rosenbaum (2002). How-
ever, in the special case in which the outcome is binary, the assumptions of this
paper simplify (as described near the end of Section 3) and a direct comparison
becomes possible. We were therefore able to include a permutation test of Rosen-
baum (2002) in our simulation study comparing the power of various methods in
Section 6. In our simulation study, the permutation test (M3) sometimes had more
power and sometimes had less power than the regression-based test (M0) of this
paper, depending on the underlying data generating distribution. We note that
except in the special case of binary outcomes, the permutation-based methods of
Rosenbaum (2002) will not have asymptotically correct Type I error for testing
the hypotheses considered in our paper in many situations. (See Web Appendix
F for an example.) This is not surprising since these methods are designed for
testing hypotheses under a different framework than considered here.
We caution that the results in this paper apply to testing the hypothesis of no
mean treatment effect within strata of selected baseline variables, but our results
do not apply to estimation of these treatment effects. The reason is that under the
alternative hypothesis, misspecified models can lead to distorted effect estimates.
Such distorted estimates, however, can be beneficial for power of hypothesis tests
when the distortion makes effect estimates more extreme (Robinson and Jewell,
1991). It is an open question how to decide which models will provide the most
power for specific alternative hypotheses, assuming models may be misspecified.
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